Nisa Investment Advisors LLC Invests $108,000 in CRISPR Therapeutics AG $CRSP

Nisa Investment Advisors LLC purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,212 shares of the company’s stock, valued at approximately $108,000.

A number of other institutional investors and hedge funds have also made changes to their positions in CRSP. Bank of New York Mellon Corp grew its stake in shares of CRISPR Therapeutics by 1.5% during the 1st quarter. Bank of New York Mellon Corp now owns 77,702 shares of the company’s stock worth $2,644,000 after purchasing an additional 1,133 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of CRISPR Therapeutics by 21.5% during the 1st quarter. Envestnet Asset Management Inc. now owns 68,058 shares of the company’s stock worth $2,316,000 after purchasing an additional 12,025 shares during the period. Axxcess Wealth Management LLC grew its stake in shares of CRISPR Therapeutics by 4.0% during the 1st quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company’s stock worth $351,000 after purchasing an additional 393 shares during the period. Leavell Investment Management Inc. acquired a new position in shares of CRISPR Therapeutics during the 1st quarter worth $340,000. Finally, Cerity Partners LLC acquired a new position in shares of CRISPR Therapeutics during the 1st quarter worth $216,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CRSP has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Wednesday, October 8th. Chardan Capital reissued a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, August 5th. Bank of America increased their price objective on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Wells Fargo & Company set a $75.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, October 13th. Finally, Zacks Research raised shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Ten investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $72.59.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,076 shares of the company’s stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the transaction, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. This represents a 1.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samarth Kulkarni sold 50,895 shares of the company’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the completion of the transaction, the chief executive officer owned 254,201 shares in the company, valued at approximately $17,262,789.91. This trade represents a 16.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 56,213 shares of company stock worth $3,810,458. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Trading Down 9.0%

NASDAQ:CRSP opened at $56.41 on Wednesday. The firm has a market cap of $5.13 billion, a price-to-earnings ratio of -10.39 and a beta of 1.89. The company’s 50-day moving average is $62.72 and its two-hundred day moving average is $52.85. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.18. The company had revenue of $0.89 million for the quarter, compared to analyst estimates of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The firm’s quarterly revenue was up 72.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.49) EPS. On average, equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.